Position of the Transparency Council – Lynparza (olaparib)
At its meeting on 15 July 2024, the Transparency Council adopted position No. 69/2024 on the evaluation of the drug Lynparza (olaparib) under the drug program “Treatment of patients with prostate cancer (ICD-10: C61)”
Publication of the position >>